0
0
Brussels, Jul 26 – In a move hailed as a major milestone in the global fight against HIV, the European Medicines Agency (EMA) has recommended the approval of lenacapavir, a revolutionary twice-yearly injectable drug developed by Gilead Sciences and marketed in Europe as Yeytuo.
A Game-Changer in HIV Prevention
The EMA announced that lenacapavir has proven “highly effective” in large-scale studies and highlighted its approval as an issue of “major public health interest.” Once formally cleared by the European Commission, the injectable will be authorized for use across all 27 EU countries, plus Iceland, Norway, and Liechtenstein.
Lenacapavir is unique as the world’s longest-lasting HIV prevention option, offering six months of protection with a single injection—far exceeding the current daily oral regimens and even the bi-monthly injectable, cabotegravir. Clinical trials showed that lenacapavir was nearly 100% effective in preventing HIV transmission among both men and women.
Reducing Stigma and Improving Access
Health experts note that a biannual injection could dramatically improve adherence and reduce the stigma associated with daily medication. It holds particular promise for high-risk groups who may struggle with the demands of daily pills or clinic visits.
Winnie Byanyima, Executive Director of UNAIDS, described lenacapavir as a potential “game-changer” and called on world leaders to prioritize broad access: “Lenacapavir could change the trajectory of the HIV epidemic,” she stated, urging global commitment to equitable distribution.
Global Rollout and Access Challenges
The US FDA approved lenacapavir for HIV prevention earlier this year, and the World Health Organization has since recommended its international rollout as an additional preventive tool.
However, questions have been raised about Gilead’s licensing policies. While Gilead allows affordable generic versions in 120 low-income countries, much of Latin America has been excluded from the agreement, despite recent increases in HIV cases in the region.
With more than 630,000 AIDS-related deaths and over 40 million people living with HIV globally in the past year alone, health advocates stress that equitable access to lenacapavir is critical if the world is to achieve ambitious HIV reduction and eradication targets.
Disclaimer: This article is based on current information available as of July 27, 2025. The content is for informational purposes only and should not be used as a substitute for medical advice. For health-related decisions, please consult a qualified healthcare professional.
